» Articles » PMID: 33614228

Oncogenic ZEB2/miR-637/HMGA1 Signaling Axis Targeting Vimentin Promotes the Malignant Phenotype of Glioma

Overview
Publisher Cell Press
Date 2021 Feb 22
PMID 33614228
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Glioma is the most common primary tumor of the central nervous system. We previously confirmed that zinc finger E-box binding homeobox (ZEB) 2 promotes the malignant progression of glioma, while microRNA-637 (miR-637) is associated with favorable prognosis in glioma. This study aimed to investigate the potential interaction between ZEB2 and miR-637 and its downstream signaling pathway in glioma. The results revealed that ZEB2 could directly bind to the E-box elements in the miR-637 promoter and promote cell proliferation, migration, and invasion via miR-637 downregulation. Subsequent screening confirmed that HMGA1 was a direct target of miR-637, while miR-637 could drive the malignant phenotype of glioma by suppressing HMGA1 both and . Furthermore, interaction between cytoplasmic HMGA1 and vimentin was observed, and vimentin inhibition could abolish increased migration and invasion induced by HMGA1 overexpression. Both HMGA1 and vimentin were associated with an unfavorable prognosis in glioma. Additionally, upregulated HMGA1 and vimentin were found in isocitrate dehydrogenase (IDH) wild-type and 1p/19q non-codeletion diffusely infiltrating glioma. In conclusion, we identified an oncogenic ZEB2/miR-637/HMGA1 signaling axis targeting vimentin that promotes both migration and invasion in glioma.

Citing Articles

Tumor and immune cell types interact to produce heterogeneous phenotypes of pediatric high-grade glioma.

DeSisto J, Donson A, Griesinger A, Fu R, Riemondy K, Mulcahy Levy J Neuro Oncol. 2023; 26(3):538-552.

PMID: 37934854 PMC: 10912009. DOI: 10.1093/neuonc/noad207.


Clinical significance of long non-coding RNA ZEB2-AS1 and EMT-related markers in ductal and lobular breast cancer.

Zarei M, Malekzadeh K, Omidi M, Mousavi P Cancer Rep (Hoboken). 2023; 6(5):e1826.

PMID: 37088469 PMC: 10172159. DOI: 10.1002/cnr2.1826.


HMGA1 As a Potential Prognostic and Therapeutic Biomarker in Breast Cancer.

Wang T, Zhou T, Fu F, Han Y, Li Y, Yuan M Dis Markers. 2022; 2022:7466555.

PMID: 36479041 PMC: 9720233. DOI: 10.1155/2022/7466555.


Circ_0000189 Promotes the Malignancy of Glioma Cells via Regulating miR-192-5p-ZEB2 Axis.

Yang J, Hou G, Chen H, Chen W, Ge J Oxid Med Cell Longev. 2022; 2022:2521951.

PMID: 36193069 PMC: 9526621. DOI: 10.1155/2022/2521951.


Dysfunction and ceRNA network of the tumor suppressor miR-637 in cancer development and prognosis.

Shen J, Liang C, Su X, Wang Q, Ke Y, Fang J Biomark Res. 2022; 10(1):72.

PMID: 36175921 PMC: 9524011. DOI: 10.1186/s40364-022-00419-8.


References
1.
Brown C, Dayan S, Wong S, Kaczmarek A, Hope C, Pederson S . FOXP3 and miR-155 cooperate to control the invasive potential of human breast cancer cells by down regulating ZEB2 independently of ZEB1. Oncotarget. 2018; 9(45):27708-27727. PMC: 6021232. DOI: 10.18632/oncotarget.25523. View

2.
Zhou J, Xie M, Shi Y, Luo B, Gong G, Li J . MicroRNA-153 functions as a tumor suppressor by targeting SET7 and ZEB2 in ovarian cancer cells. Oncol Rep. 2015; 34(1):111-20. DOI: 10.3892/or.2015.3952. View

3.
Wang L, Jiang F, Xia X, Zhang B . LncRNA FAL1 promotes carcinogenesis by regulation of miR-637/NUPR1 pathway in colorectal cancer. Int J Biochem Cell Biol. 2018; 106:46-56. DOI: 10.1016/j.biocel.2018.09.015. View

4.
Zhang J, Liu W, Zhang L, Ge R, He F, Gao T . MiR-637 suppresses melanoma progression through directly targeting P-REX2a and inhibiting PTEN/AKT signaling pathway. Cell Mol Biol (Noisy-le-grand). 2018; 64(11):50-57. View

5.
Huang Y . The novel regulatory role of lncRNA-miRNA-mRNA axis in cardiovascular diseases. J Cell Mol Med. 2018; 22(12):5768-5775. PMC: 6237607. DOI: 10.1111/jcmm.13866. View